Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from CSL ( (AU:CSL) ) is now available.
CSL Limited has updated its previously announced interim dividend details for holders of its ordinary fully paid shares, confirming that the payment relates to the six-month period ending 31 December 2025. The revised notice, dated 13 March 2026, specifies updated currency rates and local currency conversions for the dividend, following an earlier announcement on 11 February 2026.
The record date for eligible shareholders remains 11 March 2026, with the shares trading ex-dividend from 10 March 2026. The clarification on foreign exchange treatment ensures investors in different jurisdictions have transparency on their expected dividend amounts, providing greater certainty around the distribution’s value ahead of payment.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$155.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company listed on the ASX that develops and manufactures biopharmaceutical products, including vaccines and plasma-derived therapies. The company focuses on delivering treatments for serious and rare diseases and serves healthcare markets worldwide through its portfolio of specialty medicines and related services.
Average Trading Volume: 1,174,980
Technical Sentiment Signal: Sell
Current Market Cap: A$69.17B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.